San Antonio-based bioAffinity Technologies’ first cancer test ready to hit the market
Alamo City company has reached critical milestone that could lead to more commercial opportunities
SEPTEMBER 16, 2021
As published in the San Antonio Business Journal
By: W. Scott Bailey – Senior Reporter, San-Antonio Business Journal
More than seven years after its launch, bioAffinity Technologies is on the cusp of commercializing its initial product, the CyPath® Lung cancer diagnostic test.
Precision Pathology Services, which has licensed the San Antonio-based company’s technology, has completed its validation of the clinical performance of CyPath® Lung and is now preparing to take the non-invasive test to market.
“The test has met federal and state requirements to be a commercial product,” said bioAffinity President and CEO Maria Zannes. “We expect Precision Pathology to offer the test in the fall.”
Three years ago, bioAffinity struck a deal with San Antonio-based Precision Pathology to assist with the development of CyPath® Lung with the intent of commercializing its initial product as a laboratory developed test.
Zannes said a validation trial successfully tested the automated analysis program used by CyPath® Lung and found it to be fast and robust in predicting who had lung cancer and who is at high risk for the disease. She believes the market opportunities — nationally and internationally — are significant.
“Lung cancer is the leading cancer killer,” Roby Joyce, President of Precision Pathology said. “Our test for early detection of this dreaded disease can help many people live longer and healthier lives.”
BioAffinity, which conducts its research in laboratory space at the University of Texas at San Antonio, has developed a platform technology its leadership believes can lead to other product opportunities.
“The CyPath® technology can be applied to many cancers in addition to lung cancers,” Zannes said, pointing, for example, to prostate and bladder cancers.
To that end, bioAffinity’s scientific team will be working with scientists and physicians at UT Health San Antonio on further commercial applications of its core technology.